Citius Pharmaceuticals (NASDAQ:CTXR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $6.00 price target on the stock.
Citius Pharmaceuticals (NASDAQ:CTXR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences [Yahoo! Finance]